Disease · MONDO_0005361
eosinophilic esophagitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. eosinophilic esophagitis. Diseases, record MONDO_0005361. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005361
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Highest stage of its drugs
- Phase 3, for 9 of its 41 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs41
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUDESONIDE | CHEMBL1370 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| FLUTICASONE PROPIONATE | CHEMBL1473 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 7 | Drugs and targets |
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| FLUTICASONE | CHEMBL1201396 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| CENDAKIMAB | CHEMBL4297864 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 7 | 4 | 3 | Drugs and targets |
| MONTELUKAST | CHEMBL787 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| RESLIZUMAB | CHEMBL2107884 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEZEPELUMAB | CHEMBL3707229 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESOMEPRAZOLE | CHEMBL1201320 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 41
See all 41 drugsTargets31
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 3 | Potassium-transporting ATPase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 3 | Potassium-transporting ATPase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/496 | Drugs and targets |
| IL13 | Interleukin-13 | 2 | Interleukin-13 inhibitor | Phase 3 | https://conductscience.org/library/genes/3596 | Drugs and targets |
| IL5 | Interleukin-5 | 2 | Interleukin-5 inhibitor | Phase 3 | https://conductscience.org/library/genes/3567 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 1 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/240 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 agonist | Phase 2 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 1 | Muscarinic acetylcholine receptor M3 agonist | Phase 2 | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | 1 | Cysteinyl leukotriene receptor 1 antagonist | Phase 3 | https://conductscience.org/library/genes/10800 | Drugs and targets |
1 to 10 of 31
See all 31 targetsTrials71
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04753697 | A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis | Phase 3 | 430 | 2025-03-13 | Eosinophilic Esophagitis | CENDAKIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03633617 | Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) | Phase 3 | 321 | 2022-12-28 | Eosinophilic Esophagitis | DUPILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02605837 | A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved | Phase 3 | 318 | 2020-03-16 | Eosinophilic Esophagitis (EoE) | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04322708 | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis | Phase 2/3 | 277 | 2024-01-02 | Eosinophilic Esophagitis | LIRENTELIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00538434 | Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years | Phase 2/3 | 227 | 2016-09-02 | Eosinophilic Esophagitis | RESLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02736409 | An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) | Phase 3 | 219 | 2021-01-13 | Eosinophilic Esophagitis (EoE) | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04543409 | A Study of Benralizumab in Patients With Eosinophilic Esophagitis | Phase 3 | 211 | 2023-11-18 | Eosinophilic Esophagitis | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00635089 | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis | Phase 3 | 190 | 2017-03-23 | Eosinophilic Esophagitis | RESLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03245840 | Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) | Phase 3 | 133 | 2022-12-07 | Eosinophilic Esophagitis (EoE) | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02778867 | SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study | Phase 2/3 | 129 | 2020-05-26 | Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis (EoE) | FLUTICASONE PROPIONATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 71
See all 71 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oral Budesonide Suspension (OBS) vs Placebo: deaths from any cause | 0 of 213 | 0 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (AE) | 130 of 213 | 64 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: serious adverse events | 2 of 213 | 1 of 105 | 318 | NCT02605837 | Trial comparisons |
| BOS-BOS vs PBO-BOS: Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: deaths from any cause | 2 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: serious adverse events | 11 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: deaths from any cause | 0 of 23 | 0 of 24 | 47 | NCT02379052 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: serious adverse events | 3 of 23 | 0 of 24 | 47 | NCT02379052 | Trial comparisons |
| Esomeprazole vs Budesonide: Participants With Presence of Erosive Esophagitis at Six Month Endoscopy | 1 of 18 | 8 of 28 | 46 | NCT00728481 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials57
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005361
GET https://conductscience.org/api/diseases/v1/MONDO_0005361/drugs?page=2